K20

• Description:

  K20 is a potent and selective KRas G12C inhibitor with an IC50 of 1.16 μM. K20 shows anticancer activity in H358 cells (IC50= 0.78 μM) . K20 decreases the levels of phosphorylated Erk and leads to cancer cell apoptosis. K20 suppresses NCI-H358 tumor growth with a TGI of 41% without causing obvious toxicity[1].

• UNSPSC:

  12352005

• Target:

  Apoptosis; ERK; Ras

• Type:

  Reference compound

• Related Pathways:

  Apoptosis; GPCR/G Protein; MAPK/ERK Pathway; Stem Cell/Wnt

• Applications:

  Cancer-Kinase/protease

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/k20.html

• Solubility:

  10 mM in DMSO

• Smiles:

  C=C(C(N1CCN([C@@H](C1)C)C2=NC=NC3=C(C(C4=CC(Cl)=CC=C4OC)=C(C=C23)Cl)F)=O)C(F)(F)F

• Molecular Formula:

  C24H20Cl2F4N4O2

• Molecular Weight:

  543.34

• References & Citations:

  [1]Zhao H, et al. Discovery of ARS-1620 analogs as KRas G12C inhibitors with high in vivo antitumor activity. Bioorg Chem. 2022, 121:105652.

• Shipping Conditions:

  Room temperature

• Scientific Category:

  Reference compound1

• Clinical Information:

  No Development Reported

• Isoform:

  K-Ras